1. Search Result
Search Result
Results for "

oral effectiveness

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

1

Screening Libraries

2

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0223
    Albendazole
    Maximum Cited Publications
    8 Publications Verification

    SKF-62979

    Parasite Microtubule/Tubulin Autophagy Apoptosis Reactive Oxygen Species (ROS) VEGFR HIF/HIF Prolyl-Hydroxylase Antibiotic Bacterial Infection Cancer
    Albendazole (SKF-62979) is an orally active and broad-spectrum parasiticide with high effectiveness and low host toxicity, is used for the research of gastrointestinal parasites in humans and animals. Albendazole induces apoptosis and autophagy in cancer cells. Albendazole also inhibits tubulin polymerization and HIF-1α, VEGF expression, has antioxidant activity, and inhibits the glycolytic process in cancer cells .
    Albendazole
  • HY-N0787
    Cryptochlorogenic acid
    4 Publications Verification

    4-Caffeoylquinic acid; 4-O-Caffeoylquinic acid

    Endogenous Metabolite NF-κB Keap1-Nrf2 mTOR HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology
    Cryptochlorogenic acid (4-Caffeoylquinic acid) is a naturally occurring phenolic acid compound with oral effectiveness, anti-inflammatory, antioxidant and anti-cardiac hypertrophy effects. Alleviating LPS (HY-D1056) and ISO (HY-B0468) by regulating proinflammatory factor expression, inhibiting NF-κB activity, promoting Nrf2 nuclear transfer, and regulating PI3Kα/Akt/ mTOR / HIF-1α signaling pathway Induced physiological stress response .
    Cryptochlorogenic acid
  • HY-W127512
    5β-Cholanic acid
    1 Publications Verification

    Drug Intermediate Others
    5β-Cholanic acid is a hydrophobic modifier used to modify polymer carriers. 5β-Cholanic acid can improve the acid stability, cell penetration efficiency and drug sustained release ability of nanocarriers, and optimize the oral effectiveness of delivered molecules. 5β-Cholanic acid can covalently bind to Glycol chitosan (GC) to form a GC-CA conjugate, which optimizes the hydrophobic anchoring ability of nanoparticles and enables them to be stably adsorbed on the surface of PLGA nanoparticles. Such nanoparticles can resist dissociation in the gastric acid environment and maintain positive charge to enhance endocytic uptake by intestinal epithelial cells (such as Caco-2 cells). 5β-Cholanic acid can be used in the development of drug delivery systems .
    5β-Cholanic acid
  • HY-B1062

    S-(+)-Chlorpheniramine maleate salt

    Histamine Receptor Inflammation/Immunology Endocrinology
    Dexchlorpheniramine maleate is an orally taken anti-histamine that has anti-inflammatory, anti-irritant, anti-allergic, and skin barrier effects. Dexchlorpheniramine maleate inhibits myocardial contraction in rats. Dexchlorpheniramine maleate can be used in studies of allergic rhinitis .
    Dexchlorpheniramine maleate
  • HY-B0996

    NSC-17764

    Bacterial Fungal Infection Inflammation/Immunology
    Hexetidine (NSC-17764) is an orally active antibacterial and antifungal agent with broad antibacterial and antifungal activity. Hexetidine combined with IPBC potentiates strong fungal growth inhibition properties. Hexetidine at concentrations greater than 0.1% can cause oral ulceration. Additionally, Hexetidine improves its plaque inhibiting activities combined with zinc and has been confirmed the effectiveness on purulent wound along with ultrasound. Hexetidine is a promising candidate for research in fungus-related diseases and soft tissue purulent-inflammatory
    Hexetidine
  • HY-109105

    XP-23829; PPC-06

    Drug Derivative Inflammation/Immunology
    Tepilamide fumarate (XP-23829; PPC-06) is an oral fumaric acid ester, acts as a proagent ofMonomethyl fumarate (HY-103252), and is used in the research of moderate to severe chronic plaque psoriasis. Tepilamide fumarate can enhance the effectiveness of oncolytic viruses .
    Tepilamide fumarate
  • HY-B0223R

    SKF-62979 (Standard)

    Reference Standards Parasite Microtubule/Tubulin Autophagy Apoptosis Reactive Oxygen Species (ROS) VEGFR HIF/HIF Prolyl-Hydroxylase Antibiotic Bacterial Infection Cancer
    Albendazole (Standard) is the analytical standard of Albendazole. This product is intended for research and analytical applications. Albendazole (SKF-62979) is an orally active and broad-spectrum parasiticide with high effectiveness and low host toxicity, is used for the research of gastrointestinal parasites in humans and animals. Albendazole induces apoptosis and autophagy in cancer cells. Albendazole also inhibits tubulin polymerization and HIF-1α, VEGF expression, has antioxidant activity, and inhibits the glycolytic process in cancer cells .
    Albendazole (Standard)
  • HY-106296

    Enterovirus Infection
    WIN 54954 is an orally active and broad-spectrum antipicornavirus agent. WIN 54954 is effectiveness against human rhinovirus, echovirus 9 and enterovirus infections .
    WIN 54954
  • HY-106296R

    Reference Standards Enterovirus Infection
    WIN 54954 (Standard) is the analytical standard of WIN 54954. This product is intended for research and analytical applications. WIN 54954 is an orally active and broad-spectrum antipicornavirus agent. WIN 54954 is effectiveness against human rhinovirus, echovirus 9 and enterovirus infections .
    WIN 54954 (Standard)
  • HY-B0223S4

    SKF-62979-d3-1

    Reactive Oxygen Species (ROS) Cancer
    Albendazole-d3-1 (SKF-62979-d3-1) is the deuterium labeled Albendazole (HY-B0223). Albendazole (SKF-62979) is an orally active and broad-spectrum parasiticide with high effectiveness and low host toxicity, is used for the research of gastrointestinal parasites in humans and animals. Albendazole induces apoptosis and autophagy in cancer cells. Albendazole also inhibits tubulin polymerization and HIF-1α, VEGF expression, has antioxidant activity, and inhibits the glycolytic process in cancer cells .
    Albendazole-d3-1
  • HY-147678

    Free Fatty Acid Receptor Metabolic Disease
    GPR40 agonist 5 (compound I-14) is an orally active and potent GPR40 (G protein coupled receptor 40) agonist, with an EC50 of 47 nM. GPR40 agonist 5 decreases the levels of blood glucose and improves the glucose tolerance. GPR40 agonist 5 has sufficient effectiveness for the control of hyperglycemia state in type 2 diabetic mice . GPR40 agonist 5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    GPR40 agonist 5
  • HY-180339

    Infection
    Antiparasitic agent-36 is a Schistosoma mansoni-targeting antischistosomal agent that exhibits antischistosomal activity in mice with oral effectiveness, and is a nuclear substituted monoaminophenoxyalkane. Antiparasitic agent-36 can be used for the research of schistosomiasis .
    Antiparasitic agent-36
  • HY-185141

    IPK Superfamily Neurological Disease
    IP6K-IN-2 is an inositol hexakisphosphate kinase (IP6K1) inhibitor that inhibits IP6K1 enzyme activity with an IC50 value of 110 nM. IP6K-IN-2 can be used for the research of neurological disease and CNS disorders .
    IP6K-IN-2
  • HY-181644

    MetAP Infection
    NS-181 is a MetAP2 inhibitor and antiamebic agent with oral effectiveness.NS-181 functionally inhibits methionine aminopeptidase 2, a protein critical for Entamoeba histolytica proliferation. NS-181 exerts antiamebic activity against Entamoeba histolytica, leading to resolution of amebic liver abscess. NS-181 can be used for the research of amebiasis .
    NS-181
  • HY-115643

    GPR119 Metabolic Disease
    AZ13581837 is a GPR120 agonist with oral effectiveness, human EC50 values of 5.2 nM, and mouse EC50 of 4.3 nM. AZ13581837 signals through Gαq, Gαs, and β-arrestin pathways, reduces cAMP production, stimulates GLP-1 secretion, induces glucose lowering, and increases insulin secretion. AZ13581837 can be used for the research of type 2 diabetes .
    AZ13581837
  • HY-183588

    EAAT Reactive Oxygen Species (ROS) Neurological Disease
    HCM-01 is an Excitatory amino acid transporter 2 (EAAT2) activator with oral effectiveness and blood-brain barrier penetration.HCM-01 binds to the allosteric site of EAAT2, increases EAAT2 expression in astrocytes, enhances glutamate-handling capacity, and modulates glutamate homeostasis.HCM-01 acts as an antioxidant, improves oxidative/antioxidative balance and increases total antioxidant capacity. HCM-01 can be used for the research of Alzheimer's disease .
    HCM-01
  • HY-W783478

    PI3K Akt mTOR p38 MAPK NF-κB Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Calebin A is a PI3K/Akt/mTOR, MAPK, and NF-κB inhibitor with oral effectiveness. Calebin A can block the autophagy-repressive, inhibiting apoptosis. Calebin A has anti-tumor activity by epigenetic regulation. Calebin A suppresses adipogenesis, modulates thermogenesis, and enriches gut probiotics. Calebin A can be used in research on osteoarthritis, Alzheimer's disease, type 2 diabetes, malignant peripheral nerve sheath tumors, and colorectal cancer .
    Calebin A
  • HY-181917

    PANK Metabolic Disease
    Pantothenate kinase-IN-3 is an orally active PANK3-selective binder and CoA biosynthesis activator with a human PANK3 Ki of 9.1 nM, human PANK3 Ka of 1.8 nM, human PANK1β Ki of 113 nM, human PANK1β Ka of 23.4 nM, and oral effectiveness.Pantothenate kinase-IN-3 binds PANK3 via a water-mediated interaction between its sulfonamide NH and Gly193, elevates cellular, hepatic, and forebrain CoA levels, and shows improved metabolic stability in mouse and human microsomes.Pantothenate kinase-IN-3 has solubility properties favorable at pH 7.Pantothenate kinase-IN-3 can be used for the research of hepatic metabolic CoA deficiencies (acidemias) .
    Pantothenate kinase-IN-3
  • HY-180337

    Parasite Infection
    Antiparasitic agent-38 is an orally active antischistosomal agent that effectively clears Schistosoma mansoni infections in mice (single oral LD50=0.8 g/kg) and significantly inhibits S. mansoni infection. Antiparasitic agent-38 can be used for research on schistosomiasis, particularly S. mansoni infection .
    Antiparasitic agent-38
  • HY-W127512R

    Drug Intermediate Reference Standards Others
    5β-Cholanic acid is a hydrophobic modifier used to modify polymer carriers. 5β-Cholanic acid can improve the acid stability, cell penetration efficiency and drug sustained release ability of nanocarriers, and optimize the oral effectiveness of delivered molecules. 5β-Cholanic acid can covalently bind to Glycol chitosan (GC) to form a GC-CA conjugate, which optimizes the hydrophobic anchoring ability of nanoparticles and enables them to be stably adsorbed on the surface of PLGA nanoparticles. Such nanoparticles can resist dissociation in the gastric acid environment and maintain positive charge to enhance endocytic uptake by intestinal epithelial cells (such as Caco-2 cells). 5β-Cholanic acid can be used in the development of drug delivery systems .
    5β-Cholanic acid (Standard)
  • HY-183569

    c-Fms Akt PERK Aminotransferases (Transaminases) Apoptosis TNF Receptor Interleukin Related Metabolic Disease
    CSF1R-IN-27 is a CSF1R inhibitor with oral effectiveness, kinome-wide selective profile, low cellular cytotoxicity, and CSF1R IC50 values of 19 nM, 88 nM, 173 nM, 797 nM, 1448 nM, and >3000 nM. CSF1R-IN-27 suppresses M-CSF-induced phosphorylation of CSF1R, AKT, and ERK in macrophages, and inhibits hepatic p-CSF1R/p-AKT/p-ERK signaling. CSF1R-IN-27 reduces serum transaminase levels, improves hepatic histopathology, alleviates inflammatory cell infiltration, and decreases circulating TNF-α and IL-6 levels. CSF1R-IN-27 can be used for the research of acute liver injury .
    CSF1R-IN-27
  • HY-183309

    FXR 17β-HSD Inflammation/Immunology
    FXR/HSD17B13-modulator-2 is a dual FXR activator and HSD17B13 inhibitor with human FXR EC50 of 128 nM, human HSD17B13 IC50 of 0.18 μM, high selectivity over related nuclear receptors and HSD17B isoforms, and oral effectiveness.FXR/HSD17B13-modulator-2 alleviates fatty liver, regulates lipid metabolism, reduces inflammation, and attenuates hepatic fibrosis.FXR/HSD17B13-modulator-2 is the first non-carboxylic acid dual FXR/HSD17B13 modulator.FXR/HSD17B13-modulator-2 can be used for the research of metabolic dysfunction-associated steatohepatitis .
    FXR/HSD17B13-modulator-2
  • HY-186112

    P2X Receptor Inflammation/Immunology
    PSFL2915 is a P2X receptor inhibitor with oral effectiveness, with an IC50 of 0.319 μM for human P2X3, 0.261 μM for rat P2X2/3, and 13.3 μM for human P2X2, and exhibits ~42-fold selectivity for human P2X3 over human P2X2. PSFL2915 inhibits human P2X3 activation by preventing allosteric tightening of the inner pocket of the head domain required for channel opening, with magnesium-dependent inhibition. PSFL2915 inhibits rat P2X2/3 and human P2X2 receptor activation, and has low activity against human P2X1, P2X4, and P2X7 receptors. PSFL2915 can be used for the research of chronic cough .
    PSFL2915

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: